临床外科杂志 ›› 2023, Vol. 31 ›› Issue (11): 1057-1060.doi: 10.3969/j.issn.1005-6483.2023.11.015

• 论著 • 上一篇    下一篇

胃癌组织中ARHGAP4、FBLN5的表达及与病人预后的关系

  

  1. 050000  河北省石家庄市人民医院普外科一病区（周谦、孟宁、郝向东），核医学科 （刘晟楠）
  • 收稿日期:2022-12-29 修回日期:2022-12-29 接受日期:2022-12-29 出版日期:2023-11-20 发布日期:2023-11-20
  • 基金资助:
    石家庄市科技计划项目（181200963）

Expression of ARHGAP4 and FBLN5 in gastric cancer tissues and the relationship with patient prognosis

  1. Department of General Surgery Ward 1, Shijiazhuang People’s Hospital,Hebei,Shijiazhuang 050000,China
  • Received:2022-12-29 Revised:2022-12-29 Accepted:2022-12-29 Online:2023-11-20 Published:2023-11-20

PDF (PC)

283

摘要： 目的  探讨扣针蛋白5(FBLN5)、Rho GTPase激活蛋白4(ARHGAP4)在胃癌组织中的表达及与病人预后的关系。方法  2013年12月～2018年12月我院收治的胃癌病人100例，收集距肿瘤边缘>1cm处的胃癌组织以及距肿瘤边缘>5cm的癌旁组织。分析FBLN5与ARHGAP4表达情况与胃癌临床病理学指标的关系，以及其对生存状况的影响，对病人的临床资料进行单因素和多因素Cox回归分析。采用免疫组织化学染色法检测FBLN5和ARHGAP4的表达情况。利用Kaplan-Meier法分析不同ARHGAP4、FBLN5表达水平与病人生存时间的关系。结果 胃癌组织ARHGAP4阳性表达率低于癌旁组织，FBLN5的阳性表达率高于癌旁组织(P＜0.05)；ARHGAP4表达与肿瘤部位、Lauren分型、淋巴结转移、TNM分期、分化程度、CEA、CA19-9、CA125、免疫评分有关(P<0.05)；FBLN5表达与Lauren分型、淋巴结转移、TNM分期、分化程度、CE、CA19-9、CA125、免疫评分有关(P<0.05)；FBLN5高表达组病人3年累积生存率低于低表达组(P=0.044)；ARHGAP4高表达病人3年累积生存率高于低表达病人(P=0.021)；Cox分析结果显示，ARHGAP4高表达为影响生存的保护因素(P<0.05)。结论 FBLN5高表达组病人预后较低表达病人差，ARHGAP4低表达病人预后较高表达病人好。FBLN5高表达为影响生存的危险因素，二者与胃癌病人病情发展和预后密切相关。

关键词: 胃癌, 扣针蛋白5, Rho GTPase激活蛋白4, 临床病理特征

Abstract: Objective To investigate the correlation of fibulin 5(FBLN5) and Rho GTPase activating protein 4(ARHGAP4) in gastric cancer tissues and their relationship with the prognosis of patients.Methods One hundred gastric cancer patients admitted to the Department of General Surgery of Shijiazhuang First Hospital were selected for the study,and gastric cancer tissues >1cm from the tumor margin and paracancerous tissues 5cm from the tumor margin were collected.Retrospective analysis of the relationship between FBLN5 and ARHGAP4 expression profiles and clinicopathological indices of gastric cancer,as well as their effects on survival,was performed with univariate and Cox regression analyses of the patients’ clinical data.Immunohistochemical staining was used to detect the expression of FBLN5 and ARHGAP4.The relationship between the expression levels of different FBLN5 and ARHGAP4 and the survival time of patients.Results The positive expression rate of ARHGAP4 was lower than that of paracancerent tissues,and the positive expression rate of FBLN5 was higher than that of paracancerent tissues(P<0.05).ARHGAP4 expression was associated with tumor site,Lauren’s staging,lymph node metastasis,TNM stage,differentiation degree,CE,CA19-9,CA125,and immune score(P<0.05);FBLN5 expression was associated with Lauren’s staging,lymph node metastasis,TNM stage,differentiation degree,CE,CA19-9,CA125,and immune score(P<0.05);Kaplan-Meier analysis showed that the 3-year cumulative survival rate of FBLN5 positive group was,which was lower than that of negative group(P=0.044).The 3-year cumulative survival rate of ARHGAP4 positive patients was higher than that of negative patients(P=0.021).Cox results showed that positive ARHGAP4 was protective factor for survival(P<0.05).Conclusion The prognosis of patients in the FBLN5-positive group is worse than that in the negative group,high expression of FBLN5 is a risk factor for survival,and the prognosis of patients with ARHGAP4 negative group is better than that in the positive group,which are closely related to the development and prognosis of gastric cancer patients.

Key words: gastric cancer, fibulin 5, Rho GTPase activating protein 4, clinicopathological features

[1] 王青峰 陆晶晶 鲁生林 汪源 吴永丰 张明府. 新辅助化疗后行腹腔镜胃癌根治术并发症有关影响因素及预后分析[J]. 临床外科杂志, 2023, 31(9): 860-863.
[2] 李一博 宋炎阳. 胃癌腹腔镜胃远端切除术不同吻合方式对并发症及胃肠功能的影响[J]. 临床外科杂志, 2023, 31(9): 865-868.
[3] 张明燃 范玥 李俊. 胃癌根治性切除消化道重建术后Petersen疝11例临床分析[J]. 临床外科杂志, 2023, 31(9): 877-880.
[4] 马立东 刘晓蕾 赵飞. 青蒿素通过TLR4/NF-κB信号通路调节胃癌细胞的生长和炎症因子分泌的机制研究[J]. 临床外科杂志, 2023, 31(8): 738-741.
[5] 刘宇 眭超 陶亮 王萌. 胃肠道术后延迟性肠麻痹研究进展[J]. 临床外科杂志, 2023, 31(7): 698-700.
[6] 徐慧 李昊 秦静静 柳涛涛 谢昌奇 张曹. 术前血浆纤维蛋白原与非转移性胃癌病人预后关系的Meta分析[J]. 临床外科杂志, 2023, 31(4): 348-352.
[7] 李斌 杨冬 周常青. 阿帕替尼联合腹腔热灌注及静脉化疗治疗晚期胃癌腹膜转移转化治疗的效果[J]. 临床外科杂志, 2023, 31(3): 256-260.
[8] 刘炯 汪向飞 江斌. 腹腔镜辅助远端胃癌根治术不同Uncut Roux-en-y吻合方式对病人的疗效及对肿瘤标志物和预后的影响[J]. 临床外科杂志, 2023, 31(2): 177-180.
[9] 达布西力特 郑皓 韩承新. 结直肠癌组织中溴结构域蛋白4表达水平与病人临床病理特征及预后的相关性[J]. 临床外科杂志, 2023, 31(10): 949-953.
[10] 蒋祈 张鹏 陶凯雄. 美国国立综合癌症网络临床实践指南：胃癌(2022.V2)更新解读[J]. 临床外科杂志, 2023, 31(1): 18-20.
[11] 张再重 林晨 王烈. 联合脏器切除在进展期胃癌治疗中的意义[J]. 临床外科杂志, 2022, 30(9): 813-814.
[12] 黄昌明 林国生 黄泽宁 陆俊. 吲哚菁绿标记荧光示踪技术在腹腔镜胃癌根治术中的应用[J]. 临床外科杂志, 2022, 30(9): 815-818.
[13] 周岩冰. 机器人和4K腹腔镜在胃癌根治术中淋巴结清扫的比较[J]. 临床外科杂志, 2022, 30(9): 819-822.
[14] 蔺金军 刘俊华 慕立峰 黄占有 魏军龙 李永梅. 胃癌手术、介入化疗后存活19年一例[J]. 临床外科杂志, 2022, 30(9): 828-829.
[15] 莫波 王佩 童宜欣 何志军 梁俊 郝志楠. 膜解剖技术在胃癌根治术中应用的效果分析[J]. 临床外科杂志, 2022, 30(9): 835-838.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 胡志伟;汪忠镐;张玉;等. 腹腔镜Toupet胃底折叠术治疗干燥综合征合并严重胃食管反流病两例[J]. 临床外科杂志, 2016, 24(10): 766 .
[2] 张忠伟;刘扬;路明. 痔上黏膜环切术治疗直肠前突所致出口梗阻型便秘的疗效观察[J]. 临床外科杂志, 2016, 24(10): 774 .
[3] 张业强;晏大学;高小见 . 急诊肋骨内固定手术对严重连枷胸患者恢复的影响[J]. 临床外科杂志, 2016, 24(10): 794 .
[4] 贺长林;黎秋曦;刘锋;等. 腹腔镜阑尾切除术中转开腹及再手术的处理体会[J]. 临床外科杂志, 2016, 24(10): 802 .
[5] 涂儒鸿;黄昌明. 腹腔镜胃癌根治术淋巴结清扫技巧[J]. 临床外科杂志, 2016, 24(11): 809 .
[6] 陈凛;崔建新. 胃癌术后复发与再手术[J]. 临床外科杂志, 2016, 24(11): 813 .
[7] 陆林;叶哲伟;安颍;等. Ⅰ期前后路联合手术治疗复杂下颈椎骨折脱位伴关节突绞锁[J]. 临床外科杂志, 2016, 24(11): 875 .
[8] 李颢;叶达夫;李京涛;等. 双镜联合二期治疗尿道球部断裂一例[J]. 临床外科杂志, 2016, 24(11): 878 .
[9] 易凡;尚玉强;夏家红;等. 重症瓣膜病患者围手术期营养支持治疗体会[J]. 临床外科杂志, 2016, 24(12): 912 .
[10] 张华园;高峰;董军等. 颅内多发脑膜瘤一例[J]. 临床外科杂志, 2016, 24(4): 319 .
版权所有 © 《临床外科杂志》编辑部
地址：武汉市武昌区东湖路165号　邮编：430071　电话：027-87893476　E-mail: whlcwk@126.com
本系统由北京玛格泰克科技发展有限公司设计开发
鄂ICP备11011458号-3